3-fluorophenyl 1-(1,1'-biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide | 515157-02-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-fluorophenyl 1-(1,1'-biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide
• 英文别名: Tert-butyl 3-[(3-fluorophenyl)carbamoyl]-1-(4-phenylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate
• CAS: 515157-02-5
• 化学式: C₃₅H₃₂FN₃O₃
• 分子量: 561.656
• InChiKey: JRLALDWPHKSIKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  74.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Heteroaryl - fused nitrogen heterocycles as therapeutic agents
  申请人：——

  公开号：US20040014778A1

  公开（公告）日：2004-01-22

  This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.

  这项发明提供了一些作为蛋白酪氨酸磷酸酶（PTPases）抑制剂有用的化合物。作为PTPases的抑制剂，该发明的化合物可用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病。这些疾病包括I型糖尿病、II型糖尿病、免疫功能障碍、艾滋病、自身免疫疾病、葡萄糖不耐受、肥胖、癌症、牛皮癣、过敏性疾病、传染病、炎症性疾病、涉及生长激素调节合成或生长因子或影响生长激素产生的细胞因子合成的疾病，或者阿尔茨海默病。
• BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS
  申请人：TransTech Pharma Inc.

  公开号：EP1438310B1

  公开（公告）日：2006-12-20
• US6933303B2
  申请人：——

  公开号：US6933303B2

  公开（公告）日：2005-08-23
• [EN] BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS<br/>[FR] DERIVES DE BETA-CARBOLINE EN TANT QU'INHIBITEURS DE PTP
  申请人：TRANSTECH PHARMA INC

  公开号：WO2003033496A1

  公开（公告）日：2003-04-24

  This invention provides compounds of formula (I) which are u seful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.